WO2003047336A3 - TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES - Google Patents
TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES Download PDFInfo
- Publication number
- WO2003047336A3 WO2003047336A3 PCT/US2002/038245 US0238245W WO03047336A3 WO 2003047336 A3 WO2003047336 A3 WO 2003047336A3 US 0238245 W US0238245 W US 0238245W WO 03047336 A3 WO03047336 A3 WO 03047336A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- light chain
- transgenic animals
- chain genes
- animals bearing
- bearing human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17185948.1A EP3269235B1 (en) | 2001-11-30 | 2002-11-27 | Transgenic mice bearing human ig lambda light chain genes |
EP02782395.4A EP1461442B1 (en) | 2001-11-30 | 2002-11-27 | Transgenic animals bearing human ig lambda light chain genes |
DK02782395.4T DK1461442T3 (en) | 2001-11-30 | 2002-11-27 | Transgenic animals with human Ig lambda light chain genes |
CA2468565A CA2468565C (en) | 2001-11-30 | 2002-11-27 | Transgenic animals bearing human iglambda light chain genes |
JP2003548609A JP2005510253A (en) | 2001-11-30 | 2002-11-27 | Transgenic animal carrying human Igλ light chain gene |
ES02782395.4T ES2645563T3 (en) | 2001-11-30 | 2002-11-27 | Transgenic animals that carry human Ig light chain genes |
EP20159959.4A EP3698626A1 (en) | 2001-11-30 | 2002-11-27 | Transgenic animals bearing human ig lambda light chain genes |
AU2002348263A AU2002348263B2 (en) | 2001-11-30 | 2002-11-27 | Transgenic animals bearing human IgLamda light chain genes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33450801P | 2001-11-30 | 2001-11-30 | |
US60/334,508 | 2001-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003047336A2 WO2003047336A2 (en) | 2003-06-12 |
WO2003047336A3 true WO2003047336A3 (en) | 2004-06-24 |
Family
ID=23307544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/038245 WO2003047336A2 (en) | 2001-11-30 | 2002-11-27 | TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES |
Country Status (9)
Country | Link |
---|---|
US (1) | US7435871B2 (en) |
EP (4) | EP1461442B1 (en) |
JP (4) | JP2005510253A (en) |
AU (1) | AU2002348263B2 (en) |
CA (2) | CA2468565C (en) |
DK (2) | DK1461442T3 (en) |
ES (2) | ES2645563T3 (en) |
HK (1) | HK1248985A1 (en) |
WO (1) | WO2003047336A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
CA2508763C (en) * | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
BRPI0411852A (en) | 2003-06-27 | 2006-05-23 | Abgenix Inc | antibodies directed to epidermal growth factor receptor deletion mutants and their uses |
CA2564989C (en) | 2004-03-19 | 2014-05-27 | Amgen, Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
CA3079874C (en) * | 2004-10-22 | 2023-01-03 | Revivicor, Inc. | Ungulates with genetically modified immune systems |
US20080026457A1 (en) | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
CA2605964A1 (en) | 2005-04-20 | 2006-10-26 | Amgen Fremont Inc. | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies |
EP1874817A2 (en) * | 2005-04-29 | 2008-01-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
NL1029605C2 (en) * | 2005-07-25 | 2007-01-26 | Li-Te Chin | New human antibody capable of human CD152 (CTLA-4) binding or an antibody fragment, useful for diagnosing or treating human diseases caused by over- and/or under-expression of CD152 |
AR056857A1 (en) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
EP2167669A2 (en) | 2007-05-31 | 2010-03-31 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
EP2152880B1 (en) | 2007-06-01 | 2011-08-31 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
NZ592308A (en) * | 2008-09-30 | 2012-11-30 | Ablexis Llc | Non-human mammals for the production of chimeric antibodies |
EP2348827B1 (en) * | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Immunocompromised ungulates |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
EP2564695B1 (en) * | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
HUE035605T2 (en) | 2009-11-13 | 2018-05-28 | Daiichi Sankyo Europe Gmbh | Material and methods for treating or preventing HER-3 associated diseases |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
EP3095871B1 (en) | 2010-02-08 | 2019-04-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
DK2905338T3 (en) | 2010-06-22 | 2017-11-06 | Regeneron Pharma | TRANSGENE MICE WITH A MODIFIED ENDOGENT LAMBDA IMMUNGLOBULIN LOCUS |
NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
JP2013540694A (en) | 2010-08-06 | 2013-11-07 | ウー3・フアルマ・ゲー・エム・ベー・ハー | Use of HER3 binders in prostate treatment |
TWI636994B (en) | 2010-10-27 | 2018-10-01 | 安美基公司 | Dkk1 antibodies and methods of use |
HUE049154T2 (en) | 2011-05-04 | 2020-09-28 | Omeros Corp | Compositions for inhibiting masp-2 dependent complement acitivation |
EA035513B1 (en) | 2011-07-22 | 2020-06-29 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | VACCINE COMPRISING Als3 PROTEIN FOR TREATING OR PREVENTING STAPHYLOCOCCUS AUREUS SKIN ABSCESS IN A MAMMAL |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
JP2014531452A (en) * | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | Animals, repertoire and methods |
EP2759551B1 (en) | 2011-09-21 | 2019-05-22 | Fujirebio Inc. | Antibodies binding to an affinity complex comprising 25oh vitamin d2 or d3 and an antibody thereto |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
AU2012340174A1 (en) | 2011-11-16 | 2014-05-29 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
KR101924805B1 (en) | 2011-12-20 | 2018-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
RU2014141536A (en) | 2012-03-16 | 2016-05-10 | Регенерон Фармасьютикалз, Инк. | MICE WHICH PRODUCE ANTIGEN-BINDING PROTEINS WITH PH-DEPENDENT BINDING CHARACTERISTICS |
CN107827979A (en) | 2012-03-16 | 2018-03-23 | 瑞泽恩制药公司 | The engineered light chain antibody of histidine and the non-human animal through genetic modification for generating the antibody |
SI2825037T1 (en) | 2012-03-16 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents expressing ph-sensitive immunoglobulin sequences |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
JP5976380B2 (en) * | 2012-04-27 | 2016-08-23 | 公益財団法人東京都医学総合研究所 | Urokinase-type plasminogen activator transgenic mouse |
KR102381716B1 (en) | 2012-06-12 | 2022-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
WO2014130690A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
MD20150098A2 (en) | 2013-03-15 | 2016-02-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
AR095596A1 (en) | 2013-03-15 | 2015-10-28 | Amgen Res (Munich) Gmbh | UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
DE112014004537T5 (en) | 2013-10-01 | 2016-07-21 | Kymab Limited | Animal models and therapeutic molecules |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
SG11201607015VA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
JP6749312B2 (en) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Optimized interspecific bispecific single chain antibody constructs |
WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
EP4276116A3 (en) | 2015-04-17 | 2024-01-17 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
KR20180103084A (en) | 2016-02-03 | 2018-09-18 | 암젠 리서치 (뮌헨) 게엠베하 | BCMA and CD3 bispecific T cell engrafting antibody constructs |
EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
CN108883167A (en) | 2016-03-09 | 2018-11-23 | 加州大学洛杉矶分校港口医学中心生物医学研究所 | For preventing and treating the method and kit of vulvovaginal candidiasis |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
EP4082334A1 (en) | 2016-11-04 | 2022-11-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018204907A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
SG11202003044SA (en) | 2017-12-05 | 2020-04-29 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
EP3724229A1 (en) | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
JP2021532140A (en) | 2018-07-30 | 2021-11-25 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Long-term administration of bispecific antibody constructs that bind to CD33 and CD3 |
MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
CA3109732A1 (en) | 2018-08-27 | 2020-03-05 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct |
GB2576914A (en) * | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
JP2022512636A (en) | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | Downstream processing of bispecific antibody constructs |
KR20220016880A (en) | 2019-06-05 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals with a restricted lambda light chain repertoire expressed at the kappa locus and uses thereof |
TW202045711A (en) | 2019-06-13 | 2020-12-16 | 美商安進公司 | Automated biomass-based perfusion control in the manufacturing of biologics |
MX2022002981A (en) | 2019-09-10 | 2022-04-06 | Amgen Inc | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity. |
CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
UY38995A (en) | 2019-12-20 | 2021-06-30 | Amgen Inc | MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS |
KR20220119467A (en) | 2019-12-27 | 2022-08-29 | 아피메트 게엠베하 | Methods of making the bispecific FCYRIII X CD30 antibody construct |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
US20230146593A1 (en) | 2020-03-12 | 2023-05-11 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor |
KR20220155338A (en) | 2020-03-19 | 2022-11-22 | 암젠 인크 | Antibodies to mucin 17 and uses thereof |
MX2022014636A (en) | 2020-05-19 | 2023-02-23 | Amgen Inc | Mageb2 binding constructs. |
JP2023527972A (en) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3 |
IL300314A (en) | 2020-10-08 | 2023-04-01 | Affimed Gmbh | Trispecific binders |
AU2021374839A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
BR112023008670A2 (en) | 2020-11-06 | 2024-02-06 | Amgen Inc | POLYPEPTIDE CONSTRUCTS LINKED TO CD3 |
JP2023547662A (en) | 2020-11-06 | 2023-11-13 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Polypeptide constructs that selectively bind to CLDN6 and CD3 |
AU2021403010A1 (en) | 2020-12-16 | 2023-07-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
AR125290A1 (en) | 2021-04-02 | 2023-07-05 | Amgen Inc | MAGEB2 JOINING CONSTRUCTIONS |
EP4334358A1 (en) | 2021-05-06 | 2024-03-13 | Amgen Research (Munich) GmbH | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2344344A (en) * | 1998-11-03 | 2000-06-07 | Babraham Inst | Transgenic mice containing Human Ig lambda locus |
US6162963A (en) * | 1990-01-12 | 2000-12-19 | Abgenix, Inc. | Generation of Xenogenetic antibodies |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (en) * | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
FR2664073A1 (en) | 1990-06-29 | 1992-01-03 | Thomson Csf | MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING. |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2246502T3 (en) * | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
AU8546591A (en) | 1990-09-13 | 1992-04-15 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
ATE381614T1 (en) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
CA2210986A1 (en) | 1995-01-20 | 1996-07-25 | Cell Genesys, Inc. | Method to improve screening efficiency in fused cells |
ES2304786T3 (en) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
DK1500329T3 (en) * | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
TWI255853B (en) * | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2508763C (en) | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
JP6071725B2 (en) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | Driving force control device for electric vehicles |
-
2002
- 2002-11-27 JP JP2003548609A patent/JP2005510253A/en active Pending
- 2002-11-27 EP EP02782395.4A patent/EP1461442B1/en not_active Revoked
- 2002-11-27 ES ES02782395.4T patent/ES2645563T3/en not_active Expired - Lifetime
- 2002-11-27 US US10/307,231 patent/US7435871B2/en not_active Expired - Lifetime
- 2002-11-27 AU AU2002348263A patent/AU2002348263B2/en not_active Expired
- 2002-11-27 ES ES10178127.6T patent/ES2645698T3/en not_active Expired - Lifetime
- 2002-11-27 EP EP10178127.6A patent/EP2319301B1/en not_active Revoked
- 2002-11-27 CA CA2468565A patent/CA2468565C/en not_active Expired - Lifetime
- 2002-11-27 WO PCT/US2002/038245 patent/WO2003047336A2/en active Search and Examination
- 2002-11-27 DK DK02782395.4T patent/DK1461442T3/en active
- 2002-11-27 DK DK10178127.6T patent/DK2319301T3/en active
- 2002-11-27 EP EP20159959.4A patent/EP3698626A1/en not_active Withdrawn
- 2002-11-27 CA CA2847885A patent/CA2847885C/en not_active Expired - Lifetime
- 2002-11-27 EP EP17185948.1A patent/EP3269235B1/en not_active Expired - Lifetime
-
2009
- 2009-01-29 JP JP2009018855A patent/JP2009100765A/en not_active Withdrawn
-
2010
- 2010-02-04 JP JP2010023628A patent/JP2010136726A/en active Pending
-
2013
- 2013-05-07 JP JP2013097307A patent/JP2013198489A/en active Pending
-
2018
- 2018-07-10 HK HK18108945.9A patent/HK1248985A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162963A (en) * | 1990-01-12 | 2000-12-19 | Abgenix, Inc. | Generation of Xenogenetic antibodies |
GB2344344A (en) * | 1998-11-03 | 2000-06-07 | Babraham Inst | Transgenic mice containing Human Ig lambda locus |
Non-Patent Citations (2)
Title |
---|
DUELL T. ET AL.: "High-resolution physical map of the immunoglobulin lambda variant gene cluster assembled by quantitative DNA fiber mapping", GENOMICS, vol. 45, 1997, pages 479 - 486, XP004459109 * |
NICHOLSON I.C. ET AL.: "Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes", J. IMMUNOL., vol. 163, 1999, pages 6898 - 6906, XP002974255 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
Also Published As
Publication number | Publication date |
---|---|
DK2319301T3 (en) | 2017-12-04 |
EP3698626A1 (en) | 2020-08-26 |
EP2319301A2 (en) | 2011-05-11 |
EP3269235A1 (en) | 2018-01-17 |
AU2002348263B2 (en) | 2008-10-16 |
CA2847885A1 (en) | 2003-06-12 |
EP1461442B1 (en) | 2017-09-06 |
ES2645563T3 (en) | 2017-12-05 |
EP1461442A2 (en) | 2004-09-29 |
ES2645698T3 (en) | 2017-12-07 |
CA2468565C (en) | 2014-06-03 |
EP2319301A3 (en) | 2011-06-29 |
JP2005510253A (en) | 2005-04-21 |
DK1461442T3 (en) | 2017-12-04 |
CA2468565A1 (en) | 2003-06-12 |
EP2319301B1 (en) | 2017-09-06 |
CA2847885C (en) | 2022-03-22 |
JP2013198489A (en) | 2013-10-03 |
US7435871B2 (en) | 2008-10-14 |
JP2009100765A (en) | 2009-05-14 |
EP3269235B1 (en) | 2022-01-26 |
WO2003047336A2 (en) | 2003-06-12 |
US20030217373A1 (en) | 2003-11-20 |
HK1248985A1 (en) | 2018-10-26 |
EP1461442A4 (en) | 2006-11-29 |
JP2010136726A (en) | 2010-06-24 |
AU2002348263A1 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003047336A3 (en) | TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES | |
WO2005032460A3 (en) | Human epo mimetic hinge core mimetibodies, compositions, methods and uses | |
NO20034056D0 (en) | Proliferative diseases | |
WO2003084477A3 (en) | Mammalian cdr mimetibodies, compositions, methods and uses | |
GB2302022A (en) | Multifunctional biodispersant/biocidal compositions | |
ZA200108684B (en) | Method of enhancing biological effectiveness of plant treatment compositions. | |
DE60326150D1 (en) | Anisic acid and glyceride containing compositions | |
EP1055720A3 (en) | Compositions for stabilizing oxygen-labile species | |
WO2001034647A3 (en) | Animal collagens and gelatins | |
WO2002073208A3 (en) | Anti-epileptogenic agents | |
WO2004087073A3 (en) | Treatment of demyelinating conditions | |
TR199902257T2 (en) | Tetrahidropirido bile�ikleri | |
IT1303472B1 (en) | SHOE PARTICULARLY SUITABLE FOR FREE CLIMBING. | |
WO2002018954A3 (en) | Inhibition of cmv infection and dissemination | |
ATE277026T1 (en) | NAPHTHYL COMPOUNDS, COMPOSITIONS AND METHODS | |
PL340459A1 (en) | Agonists of 5ht1f | |
EP2161276A3 (en) | Methods, compositions and libraries pertaining PNA dimer and PNA oligomer systhesis | |
ID28203A (en) | MAKING SIANOVALERATE ACID OR ESTERS FROM IT | |
ATE295686T1 (en) | COMPOSITIONS FOR DETERRING CRAWING INSECTS | |
WO2003049696A3 (en) | Glucosamine organic acid adducts | |
WO2004026892A3 (en) | Fragmentation of dna | |
BR0209828A (en) | Organic compounds | |
WO2004050834A3 (en) | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER | |
ATE245637T1 (en) | BENZOTHIOPHENE COMPOUNDS, PREPARATIONS AND METHODS | |
WO2002028183A8 (en) | Fungicides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2468565 Country of ref document: CA Ref document number: 2003548609 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002348263 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2002782395 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002782395 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2002782395 Country of ref document: EP |